Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JNJ-53718678 in young children with acute RSV respiratory tract infection
2016-003642-93Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rilematovir in respiratory syncytial virus disease (RSV), acute respiratory illness (ARI), sponsored by Janssen Pharmaceutical. Status: unknown.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)acute respiratory illness (ARI)
Beyond the preview
Go deeper on 2016-003642-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003642-93.